Insider Transactions
| Date | Name | Title | Type | Shares Traded | Price Range |
|---|---|---|---|---|---|
| Feb 23, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Other acquisition or disposition | -- | -- |
| Feb 23, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Other acquisition or disposition | -- | -- |
| Feb 23, 2021 |
Director, CEO & President
|
Director, CEO & President | Other acquisition or disposition | -- | -- |
| Feb 22, 2021 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Open market or private sale of non-derivative or derivative security | 4,000 | $3.73 |
| Feb 22, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 4,000 | $3.73 |
| Feb 22, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Open market or private sale of non-derivative or derivative security | 5,000 | $3.73 |
| Feb 22, 2021 |
Director, CEO & President
|
Director, CEO & President | Open market or private sale of non-derivative or derivative security | 7,500 | $3.73 |
| Feb 19, 2021 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Open market or private sale of non-derivative or derivative security | 4,672 | $3.64 |
| Feb 19, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Open market or private sale of non-derivative or derivative security | 3,295 | $3.64 |
| Feb 19, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Open market or private sale of non-derivative or derivative security | 5,018 | $3.64 |
| Feb 19, 2021 |
Director, CEO & President
|
Director, CEO & President | Open market or private sale of non-derivative or derivative security | 7,257 | $3.64 |
| Feb 18, 2021 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 119,579 | -- |
| Feb 18, 2021 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 144,944 | -- |
| Feb 18, 2021 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 340,618 | -- |
| Feb 18, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 110,309 | -- |
| Feb 18, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 133,708 | -- |
| Feb 18, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 314,213 | -- |
| Feb 18, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 110,309 | -- |
| Feb 18, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 133,708 | -- |
| Feb 18, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 314,213 | -- |
| Feb 18, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 134,410 | -- |
| Feb 18, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 162,921 | -- |
| Feb 18, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 382,865 | -- |
| Feb 18, 2021 |
Director, CEO & President
|
Director, CEO & President | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 278,090 | -- |
| Feb 18, 2021 |
Director, CEO & President
|
Director, CEO & President | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 337,079 | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.